291.72
price up icon1.69%   4.84
pre-market  Pre-market:  291.72  
loading
United Therapeutics Corp stock is traded at $291.72, with a volume of 641.28K. It is up +1.69% in the last 24 hours and down -4.46% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$286.88
Open:
$287.98
24h Volume:
641.28K
Relative Volume:
1.22
Market Cap:
$12.69B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
11.64
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+5.52%
1M Performance:
-4.46%
6M Performance:
-18.41%
1Y Performance:
-4.68%
1-Day Range:
Value
$282.89
$292.74
1-Week Range:
Value
$275.50
$292.74
52-Week Range:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Name
United Therapeutics Corp
Name
Phone
(301) 608-9292
Name
Address
1000 SPRING ST, SILVER SPRING, MD
Name
Employee
1,305
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
291.72 12.69B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
63.35 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.06 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.90 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.06 20.17B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Initiated Cantor Fitzgerald Overweight
Apr-25-25 Downgrade Wells Fargo Overweight → Equal Weight
Apr-21-25 Upgrade BofA Securities Underperform → Neutral
Jul-11-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-12-24 Upgrade Goldman Sell → Neutral
Feb-05-24 Initiated Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Dec-06-22 Initiated UBS Buy
Dec-05-22 Initiated Goldman Sell
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-20-22 Reiterated BofA Securities Underperform
Sep-19-22 Resumed Wedbush Outperform
Feb-11-22 Initiated BTIG Research Neutral
Jul-14-21 Upgrade Argus Hold → Buy
Apr-26-21 Resumed Credit Suisse Outperform
Feb-01-21 Upgrade H.C. Wainwright Neutral → Buy
Sep-14-20 Resumed JP Morgan Overweight
Jun-25-20 Reiterated H.C. Wainwright Neutral
Mar-10-20 Upgrade Jefferies Hold → Buy
Feb-27-20 Upgrade Cowen Market Perform → Outperform
Jan-31-20 Upgrade JP Morgan Neutral → Overweight
Dec-03-19 Initiated BofA/Merrill Underperform
Aug-01-19 Upgrade Jefferies Underperform → Hold
Aug-01-19 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-01-19 Upgrade Credit Suisse Neutral → Outperform
May-17-19 Upgrade UBS Sell → Neutral
May-09-19 Upgrade Credit Suisse Underperform → Neutral
Oct-12-18 Upgrade Standpoint Research Hold → Buy
Aug-08-18 Downgrade Credit Suisse Neutral → Underperform
Apr-03-18 Upgrade Credit Suisse Underperform → Neutral
Feb-22-18 Reiterated Barclays Underweight
Jan-18-18 Resumed Credit Suisse Underperform
Dec-27-17 Reiterated Wedbush Outperform
Apr-27-17 Reiterated Wedbush Outperform
Mar-30-17 Initiated UBS Sell
Mar-16-17 Initiated Credit Suisse Underperform
View All

United Therapeutics Corp Stock (UTHR) Latest News

pulisher
Jun 17, 2025

United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com

Jun 16, 2025
pulisher
Jun 15, 2025

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga

Jun 15, 2025
pulisher
Jun 11, 2025

United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 06, 2025

Treprostinil Saga Continues - JD Supra

Jun 06, 2025
pulisher
Jun 06, 2025

United Therapeutics president sells shares worth $3.7 million - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com

Jun 04, 2025
pulisher
Jun 03, 2025

United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 29, 2025

Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360

May 29, 2025
pulisher
May 29, 2025

United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 29, 2025
pulisher
May 29, 2025

Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo

May 29, 2025
pulisher
May 27, 2025

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com

May 26, 2025
pulisher
May 24, 2025

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey

May 24, 2025
pulisher
May 24, 2025

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World

May 24, 2025
pulisher
May 23, 2025

FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World

May 23, 2025
pulisher
May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025
pulisher
May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025
pulisher
May 15, 2025

Construction underway for new United Therapeutics facility in Stewartville - KTTC News

May 15, 2025
pulisher
May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025
pulisher
May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025
pulisher
May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025
pulisher
May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025
pulisher
May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025

United Therapeutics Corp Stock (UTHR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

United Therapeutics Corp Stock (UTHR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
MAHON PAUL A
EVP & GENERAL COUNSEL
Jun 12 '25
Sale
279.96
11,000
3,079,514
36,781
$127.31
price up icon 1.95%
drug_manufacturers_specialty_generic RDY
$15.19
price down icon 0.39%
$8.77
price up icon 0.11%
$13.33
price down icon 2.06%
$17.06
price up icon 1.01%
Cap:     |  Volume (24h):